News | Heart Valve Technology | May 17, 2016

NeoChord Receives FDA Approval to Begin Clinical Trial of DS1000 System

Pivotal study will enroll up to 450 patients in a randomized trial of Artificial Chordae Delivery System for treatment of degenerative mitral valve regurgitation

NeoChord, DS1000 System, FDA approval, U.S. pivotal trial

May 17, 2016 — NeoChord Inc. announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a prospective, multicenter, randomized clinical trial for its Artificial Chordae Delivery System, DS1000.

The pivotal trial will be conducted at 20 U.S. mitral repair centers, according to Lori Adels, Ph.D., vice president of clinical, regulatory and quality at NeoChord. Adels said it is the first U.S. clinical study of a transapical, beating heart procedure for replacement of ruptured or elongated chordae in patients with degenerative mitral valve regurgitation.

Trial protocol was developed in consultation with the FDA and principal investigators David H. Adams, M.D, professor and chairman, Department of Cardiovascular Surgery, Icahn School of Medicine at Mt. Sinia, New York; and Michael A. Borger, M.D., Ph.D., professor and director, Cardiovascular Institute, New York Presbyterian/Columbia University Medical Center, New York. The trial is designed to establish the safety and efficacy of the DS1000 System as an alternative to standard surgical mitral valve repair.

NeoChord received CE Marking approval for the DS1000 System in December 2012 and began marketing the product in Q1 2013. The company plans to expand the commercial availability of the DS1000 System to additional European markets throughout 2016 and 2017.

For more information: www.neochord.com

Related Content

Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
Overlay Init